Document is current

Article History

Received: 26 November 2025

Accepted: 30 March 2026

First Online: 3 May 2026

Declarations

:

: This study was approved by the Salus Institutional Review Board on 20 January 2023 (#23007-01). This study was performed in accordance with the Declaration of Helsinki of 1964 and its later amendments. Before completing any study-related activities, participants provided informed consent to participate in the study. Participants under 18 years of age provided assent, and their caregiver provided informed consent. No investigational drugs, devices, or invasive procedures were administered or evaluated.

: J.M. was an employee of Sanofi at the time this study was conducted and may hold shares or stock options in the company. C.R., K.I.B., and S.B. are current employees of Sanofi and may hold shares or stock options in the company. G.S.F., K.C., and M.Q. are employees of Evidera PPD, Thermo Fisher Scientific, which received funds paid by Sanofi to Thermo Fisher Scientific for work relating to this study.

: Some results were previously presented in a poster at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting, September 2024, Toronto, ON, Canada.